Biohaven Ltd. (BHVN)

Biohaven Expands Asian Licensing Footprint Through Strategic Ono Agreement

Biohaven Enters Strategic Licensing Agreement with Ono Pharma for Extracellular IgG Degraders in Japan and Select Asian Regions, Lead Candidate BHV-1300 in Phase 3 for Graves' Disease

Biohaven Enters Strategic Licensing Agreement with Ono Pharma for Extracellular IgG Degraders in Japan and Select Asian Regions, Lead Candidate BHV-1300 in Phase 3 for Graves' Disease

Biohaven's Clinical Data on BHV-1530, a Novel FGFR3-Directed ADC With a Proprietary Topoisomerase I (TopoIx) Payload, Selected for Oral Presentation at the EORTC-NCI-AACR Symposium 2026

Biohaven's Clinical Data on BHV-1530, a Novel FGFR3-Directed ADC With a Proprietary Topoisomerase I (TopoIx) Payload, Selected for Oral Presentation at the EORTC-NCI-AACR Symposium 2026

Biohaven Investigation Notice: SueWallSt Notifies Investors of Pending Investigation Into Biohaven (BHVN)

Biohaven Stock Is Sinking. Epilepsy Drug Trial Roadblock Is Only the Latest Blow.

FDA Pauses New Enrollment for Biohaven Epilepsy Drug Program

US FDA pauses new enrollment in Biohaven's epilepsy drug trials

BlackRock Inc. Invests $196.57 Million in Biohaven Ltd. $BHVN

Why Biohaven Stock Was Rocking the Market This Week

Biohaven: Buy Reiterated On Opakalim License Agreement For Epilepsy And More

Biohaven: Sale Of Opakalim Rights To SK Biopharmaceuticals Makes Sense On Many Levels

BHVN Stock Soars 18% on $795M Out-Licensing Deal for Epilepsy Program

Why Is Biohaven Stock Soaring Wednesday?

Biohaven and SK Biopharmaceuticals Enter into Strategic Global Licensing Agreement for Novel Kv7 Ion Channel Platform and Opakalim, Lead Candidate for Epilepsy

Biohaven licenses epilepsy drug to South Korea's SK Biopharmaceuticals for up to $795 million

Biohaven and SK Biopharmaceuticals Enter into Strategic Global Licensing Agreement for Novel Kv7 Ion Channel Platform and Opakalim, Lead Candidate for Epilepsy

Federal Court Enters Judgment Confirming RA Capital and Avilar Therapeutics Willfully and Maliciously Misappropriated Trade Secret Developed at Yale, Formalizing $4 Million Award to Biohaven and Yale University

Biohaven Reports Recent Business Developments and Second Quarter 2026 Financial Results